Healthcare Heads GmbH

💡 FAQ #5 about the new #Hybrid-#DRGs: Will #reimbursement now decrease? As part of our Hybrid-DRG FAQ series, we’re addressing one of the most pressing questions for manufacturers and providers in the German healthcare market. The calculation of the German DRG reimbursement is based on the valuation ratio (relative weight) multiplied by the current federal base rate. This means that DRG reimbursement is directly linked to actual treatment costs. Under the new Hybrid-DRGs, reimbursement is also cost-based, including outpatient treatment cases on a pro ratio basis. So, what does this mean in practice? ➡️ Costs are transferred from inpatient reimbursement to the Hybrid-DRGs, which reduces total reimbursement for inpatient treatment cases. ➡️ At the same time, reimbursement for the treatment cases that are now billed through Hybrid-DRGs is also reduced. As a result, both the previous and the new reimbursement levels are lower. What impact could this have on your product and strategy? Learn how these changes may affect your #MarketAccess and #Reimbursement approach and how to proactively adapt. 📩 Contact us for tailored insights: [email protected] 🔎 Stay tuned for more updates in our Hybrid-DRG FAQ series - we’ll continue answering the key questions you need to know. #HybridDRG #MarketAccess #Reimbursement #Innovation #MedTech #GermanHealthcareSystem #HealthEconomics #HealthcareStrategy

#Hybrid-#DRGs Cross-sector reimbursement opens up new doors, but it also comes with complex challenges. Hybrid-DRGs are fundamentally transforming the German healthcare system. Hospitals, outpatient service providers, and the MedTech industry now face new opportunities and critical strategic decisions. At Healthcare Heads, we act as your strategic partner: 👉🏻 We break down the changes and explain their implications. 👉🏻 We help you assess the impact on your reimbursement strategy. 👉🏻 Together, we develop tailored solutions that maximize your success. 🔗 Discover more on our new Hybrid-DRG page: https://lnkd.in/eR-uWArV Contact us to learn how to navigate this evolving landscape and turn challenges into opportunities. 📩 [email protected] #MarketAccess #Reimbursement #DRG #GermanHealthcare #HybridDRG

💡 FAQ #5 about the new #Hybrid-#DRGs: What changes will apply from 2026? As part of our Hybrid-DRG FAQ series, we explore the significant updates coming to Germany’s healthcare reimbursement landscape. From 2026 onwards, the service catalog for Hybrid-DRGs will be expanded to include procedures that have never before been performed on an outpatient basis in Germany with hospital stays of up to three days (two overnight stays). At the same time, billing processes will be further standardized to ensure uniform reimbursement between hospitals and contracted physicians. The affected services must be mandatorily billed through the Hybrid-DRG system. What opportunities and challenges does this create for your product? Is your #MarketAccess and #Reimbursement strategy ready? Learn how the new Hybrid-DRGs can impact your market access strategy, and how to prepare effectively. Contact us for a complimentary consultation. 📩 [email protected] 🔎 Stay tuned for more insights in our Hybrid-DRG FAQ series – we’ll continue answering the key questions you need to know. #MarketAccess #Reimbursement #HybridDRG #Innovation #MedTech #GermanHealthcareSystem

📄 Reminder: White Paper on #German #Hospital #Financing #Reform available Do you understand the impact of the #KHVVG on your market access and reimbursement strategy? Germany’s hospital financing reform (KHVVG) introduces significant changes to the healthcare system, creating uncertainty for hospitals and medical technology providers. Our latest #white #paper highlights key challenges and explains how the reform may affect the financing of innovative products. 🔗 Download now for free and stay informed: https://lnkd.in/gUPayJX As experts in Market Access and Reimbursement, we are here to support you in making the right strategic decisions. Contact us if you would like to know how you can beste prepare your products for the upcoming regulatory and economic changes. 📩 [email protected] #MarketAccess #Reimbursement #GermanHealthcare #MedTech #Reform #whitepaper

DRG System 2026: Insights from the 25th #DGfM #Autumn #Symposium On October 13, 2025, the 25th Autumn Symposium of the German Society for Medical Controlling (Deutsche Gesellschaft für Medizincontrolling e.V. (DGfM) took place in Frankfurt. Our CEO, Sven Sauermann, was on-site and shares the latest updates on the DRG system for 2026. As is tradition, the first day of the event was devoted entirely to the DRG system. Leading experts in the field of hospital financing discussed current issues relating to the Hospital Care Improvement Act (KHVVG) and the Hospital Adjustment Act (KHAG). As usual, Dr. Frank Heimig, head of InEK, concluded the event with an outlook on the upcoming changes for 2026. This was his first public presentation of insights into the future direction of the DRG system in 2026. A central topic was the restructuring of the DRG system in the course of defining #Hybrid-#DRGs. Although the underlying cost data has already been determined by InEK and forwarded to InBA in recent days, an agreement by the self-governing body is still pending. This could lead to further adjustments to the DRG system 2026, including possible changes to DRG definitions and the DRG catalog. What does this mean for your product and your market strategy? The upcoming changes may have a direct impact on your positioning in the German healthcare market. Contact us if you would like to know how you can best prepare your products for the upcoming regulatory and economic changes. 📩 [email protected] 🔗 Visit our website for information: https://lnkd.in/emnkBU-i #MarketAccess #Reimbursement #HealthcareStrategy #DRG2026 #DGfM #HospitalFinancing

💡 FAQ #4 about the new #German #Hybrid-#DRGs: Why were Hybrid-DRGs introduced in the first place? As part of our Hybrid-DRG FAQ series, we explore why Germany is implementing cross-sector reimbursement for certain medical treatments. Compared to other countries, more patients in Germany are treated as in-patients, which leads to higher costs without improving quality. The new Hybrid-DRGs apply equally to registered contract doctors and hospitals, creating incentives for more patients to shift from inpatient to outpatient care. Would you like to learn how the new Hybrid-DRGs may impact your product? Contact us for a complimentary consultation with our experts. 📩 [email protected] 🔎 Stay tuned for more insights in our Hybrid-DRG FAQ series – we’ll continue answering the key questions you need to know. #MarketAccess #Reimbursement #HybridDRG #Innovation #MedTech #GermanHealthcareSystem

📢 German Hospital Reform Update: Cabinet Approves #KHAG Adjustment Act 📄 On October 8, 2025, the German Federal Cabinet approved the draft #Hospital #Reform Adjustment Act (KHAG), aiming to make the original reform more practical. The adjustments provide more flexibility for states and hospitals, but key questions about long-term financing, feasibility, and bureaucracy remain open. Key highlights of the KHAG adjustment: 👉🏻Regional adaptability: Federal states can decide on exemptions and cooperation models between healthcare providers, supporting care in rural areas. 👉🏻Service groups: Hospital services will be grouped into 61 categories for streamlined implementation of new quality criteria. 👉🏻Onco-surgery: Reduced case number thresholds to secure comprehensive and specialized care. 👉🏻Transformation fund: Up to €25 billion over ten years, plus an additional €1 billion annually for four years, to support hospitals and relieve state budgets. University hospitals may also receive subsidies. 👉🏻Pre-Reimbursement: Introduction and supplements postponed by one year; existing pediatric and obstetrics supplements extended. 💡 The key question: How will these changes shape the future healthcare landscape, planning authority, and financing system in Germany? At Healthcare Heads, we specialize in market access and reimbursement in the German healthcare market. We analyze the impact of KHAG on structural planning, reimbursement systems, and investment decisions, helping you navigate potential opportunities and challenges for your product. Contact us for a complimentary consultation to explore how the reform might affect your strategy. 📩[email protected] #Healthcare #HospitalReform #MarketAccess #Reimbursement #Germany #KHAG #HealthPolicy

💡 FAQ #3 about the new #German #Hybrid-#DRGs: What does “#cross-#sector” reimbursement mean? As part of our Hybrid-DRG FAQ series, we take a closer look at how reimbursement is evolving across care settings. Until now, inpatient services in hospitals were often reimbursed at higher rates than services provided by contract physicians under the EBM (German medical fee schedule). With cross-sector, uniform reimbursement through Hybrid-DRGs, contract physicians can now perform and bill certain services at the same rate as inpatient care. 🚀 Understanding these changes is crucial for product strategy, market access, and reimbursement planning. Would you like to learn how the new Hybrid-DRGs may impact your product? Contact us for a complimentary consultation with our experts. 📩 [email protected] 🔎 Stay tuned for more insights in our Hybrid-DRG FAQ series – we’ll continue answering the key questions you need to know. #MarketAccess #Reimbursement #HybridDRG #Innovation #MedTech #GermanHealthcareSystem

📄 Unser neues HcH #Whitepaper: Die deutsche Krankenhausfinanzierungsreform – blicken Sie noch durch? 🏥 Was als bahnbrechende Reform des deutschen Gesundheitswesens gedacht war, sorgt nun für massive Turbulenzen im System. Die #KHVVG-#Reform verändert die Krankenhausfinanzierung und schafft Unsicherheit für Krankenhäuser und ihre Medizintechnik-Anbietern. Der deutsche Gesundheitsmarkt ist bekannt für seine Komplexität. Die Finanzierung von Krankenhäusern in einem solidarisch finanzierten System stellt eine besondere Herausforderung für den Marktzugang innovativer medizinischer Produkte dar. Wenn Sie sich fragen, welche Auswirkungen das neue Gesetz auf das bestehende Finanzierungssystem hat und wie sich diese möglicherweise auf Ihr Produkt auswirken können, oder wenn Sie die Mechanismen des deutschen Gesundheitsmarktes im Allgemeinen besser verstehen möchten, dann ist unser kostenloses Whitepaper zur deutschen Krankenhausfinanzierungsreform genau das Richtige für Sie. 🔗 Hier geht‘s zum Download: https://lnkd.in/eUwPqguY 💡 Wir sind Experten für Market Access und Reimbursement und unterstützen Sie gerne dabei, den Erfolg Ihres Produkts sicherzustellen. Kontaktieren Sie uns für ein kostenloses Beratungsgespräch. 📩 [email protected] #Whitepaper #MarketAccess #Reimbursement #MedTech #Krankenhausreform #Deutschland

💡 FAQ #2 about the new #German #Hybrid-#DRGs: Which services can be billed using Hybrid-DRGs? As part of our Hybrid-DRG FAQ series, we take a closer look at the types of services covered under the new system. Hybrid-DRGs can be used to bill for a defined set of “simple” surgical procedures, which can also be safely performed outside of a hospital setting. Examples include certain hernia surgeries, now listed in the 2024 Hybrid-DRG catalog. This catalog is set to be continuously expanded, reflecting ongoing updates in healthcare delivery and reimbursement. 🚀 Understanding these changes is crucial for product strategy, market access, and reimbursement planning. Would you like to learn how the new Hybrid-DRGs may impact your product? Contact us for a complimentary consultation with our experts. 📩 [email protected] 🔎 Stay tuned for more insights in our Hybrid-DRG FAQ series – we’ll continue answering the key questions you need to know. #MarketAccess #Reimbursement #HybridDRG #Innovation #MedTech #GermanHealthcareSystem